Reunion Neuroscience Inc. (TSE:REUN – Get Free Report) fell 2.7% during trading on Monday . The company traded as low as C$1.41 and last traded at C$1.42. 339 shares changed hands during trading, a decline of 97% from the average session volume of 12,447 shares. The stock had previously closed at C$1.46.
Reunion Neuroscience Price Performance
The stock has a market cap of C$16.64 million, a price-to-earnings ratio of -0.43 and a beta of 4.20. The stock’s 50 day simple moving average is C$1.42.
Reunion Neuroscience Company Profile
Reunion Neuroscience Inc, a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Read More
- Five stocks we like better than Reunion Neuroscience
- What Does Downgrade Mean in Investing?
- Buffett Bails on BYD: What It Means for the Future of EV Stocks
- How to Start Investing in Real Estate
- Domino’s vs. Papa John’s: Stock Showdown of Pizza Giants
- What Are the FAANG Stocks and Are They Good Investments?
- Williams-Sonoma Makes Stock More Accessible with a Stock Split
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
